Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmi...(ent Form 10-K and include but are not li...),Health

Date:11/6/2009

ent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, material litigation from product recalls, the purported class action lawsuits alleging federal securities laws violations, delays in returning the Company's products to market, including loss of market share, increased reserves against the FDA-seized inventory, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
3. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
4. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
6. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
7. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
8. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
9. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
10. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
11. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results